Compounds > fluorobenzenes
Page last updated: 2024-08-21

fluorobenzenes and Anterior Choroidal Artery Infarction

fluorobenzenes has been researched along with Anterior Choroidal Artery Infarction in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (50.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liu, B; Wang, FJ; Wang, YN; Zhang, JY; Zhang, WN1
Deguchi, I; Fukuoka, T; Hayashi, T; Horiuchi, Y; Kato, Y; Maruyama, H; Nagamine, Y; Ohe, Y; Sano, H; Sehara, Y; Tanahashi, N1
Doerfler, A; Engelhorn, T; Heusch, G; Schulz, R1
Böhm, M; Dirnagl, U; Endres, M; Gertz, K; Laufs, U; Nickenig, G1

Other Studies

4 other study(ies) available for fluorobenzenes and Anterior Choroidal Artery Infarction

ArticleYear
Effect of rosuvastatin on OX40L and PPAR-γ expression in human umbilical vein endothelial cells and atherosclerotic cerebral infarction patients.
    Journal of molecular neuroscience : MN, 2014, Volume: 52, Issue:2

    Topics: Case-Control Studies; Cerebral Infarction; Female; Fluorobenzenes; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Arteriosclerosis; Male; OX40 Ligand; PPAR gamma; Pyrimidines; Rosuvastatin Calcium; Sulfonamides

2014
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:8

    Topics: Adult; Arteriosclerosis; C-Reactive Protein; Carotid Intima-Media Thickness; Cerebral Infarction; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors; Treatment Outcome; Triglycerides

2014
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
    Neuroscience letters, 2006, Oct-02, Volume: 406, Issue:1-2

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Brain; Cerebral Infarction; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Ischemic Attack, Transient; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Treatment Outcome

2006
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
    Brain research, 2002, Jun-28, Volume: 942, Issue:1-2

    Topics: Animals; Brain Ischemia; Cells, Cultured; Cerebral Infarction; Cerebrovascular Circulation; Dose-Response Relationship, Drug; Endothelium, Vascular; Fluorobenzenes; Gene Expression Regulation, Enzymologic; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infarction, Middle Cerebral Artery; Mice; Mice, Inbred Strains; Neuroprotective Agents; Nitric Oxide Synthase; Pyrimidines; Reperfusion Injury; RNA, Messenger; Rosuvastatin Calcium; Stroke; Sulfonamides; Up-Regulation

2002